Study of Avelumab-M3814 Combinations
Public ClinicalTrials.gov record NCT03724890. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors
Study identification
- NCT ID
- NCT03724890
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Enrollment
- 57 participants
Conditions and interventions
Conditions
Interventions
- M3814 Drug
- Avelumab Drug
- Radiotherapy Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2018
- Primary completion
- Aug 31, 2021
- Completion
- Aug 16, 2022
- Last update posted
- Apr 9, 2025
2018 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| H. Lee Moffitt Cancer Center and Research Institute, Inc | Tampa | Florida | 33612 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Mount Sinai - PRIME (10707) | Lake Success | New York | 11041 | — |
| UC Health Clinical Trials Office (10702) | Cincinnati | Ohio | 45267-0502 | — |
| University of Oklahoma Health Sciences Center - Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Pittsburgh Medical Center Health System | Pittsburgh | Pennsylvania | 15213 | — |
| Greenville Hospital System University Medical Center (ITOR) | Greenville | South Carolina | 29605 | — |
| Vanderbilt-Ingram Cancer Center (8867) | Nashville | Tennessee | 37212 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03724890, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 9, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03724890 live on ClinicalTrials.gov.